AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8.
ByAinvest
Tuesday, Aug 12, 2025 10:53 am ET1min read
RAPT Therapeutics: UBS maintains Neutral, raises PT to $9 from $8.
July 2, 2025In a recent update, UBS Financial Services has revised its price target for RAPT Therapeutics (NASDAQ: RAPT) from $8 to $9. This adjustment reflects the investment bank's analysis of the company's financial performance and strategic developments. The updated price target is based on a neutral rating, indicating a balanced view of RAPT's prospects.
Financial Performance
RAPT Therapeutics reported its first quarter 2025 financial results, showing a significant improvement in net loss to $17.2 million compared to $30.5 million in Q1 2024 [1]. The company's research and development expenses decreased to $12.0 million from $24.8 million year-over-year, while general and administrative expenses slightly decreased to $7.2 million from $7.7 million. Despite the net loss, RAPT maintained a strong cash position of $179.3 million as of March 31, 2025.
Clinical Progress
The company's CEO, Brian Wong, highlighted progress with RPT904, a food allergy treatment candidate, with plans to initiate a Phase 2b trial in H2 2025. The company is also anticipating clinical data for RPT904 in chronic spontaneous urticaria (CSU) from their partner Jemincare later this year [1].
Strategic Appointments
RAPT has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development of RPT904. Dr. Savage brings significant expertise in food allergy research and clinical development, having previously held leadership positions at Harvard Medical School, Johns Hopkins University, and Alexion [2].
Investor Conferences
RAPT Therapeutics has announced its participation in several investor conferences in 2025, including the Goldman Sachs 46th Annual Global Healthcare Conference and the UBS Spring Biotech Conference. These events provide opportunities for the company to present its progress and engage with investors [3].
UBS Analysis
UBS analysts have noted the company's strong pipeline, particularly the potential of RPT904, and the strategic appointment of Dr. Savage. The investment bank expects the company's clinical trials and partnerships to drive growth and improve financial performance.
References
[1] https://www.stocktitan.net/news/RAPT/
[2] https://www.stocktitan.net/news/RAPT/2025/03/07/108437/
[3] https://www.stocktitan.net/news/RAPT/2025/06/04/108437/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet